Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPTH(1-84) for symptomatic adult hypoparathyroidism
2017-000284-32Phase 3Unknown
- Sponsor
- Takeda
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoparathyroidism and Congenital hypoparathyroidism comparing rhPTH(1-84) with Placebo (2 arms). Primary endpoint: Change in HPT-SD symptom subscale score from baseline. Status: unknown.
02
Drugs
parathyroid hormone 1-84
03
Conditions
hypoparathyroidismCongenital hypoparathyroidism
Beyond the preview
Go deeper on 2017-000284-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000284-32.